1.
|
HB El-SeragHepatocellular carcinomaN Engl
J Med36511181127201110.1056/NEJMra100168321992124
|
2.
|
SH CaldwellDM CrespoHS KangAM
Al-OsaimiObesity and hepatocellular
carcinomaGastroenterology127Suppl
1S97S103200410.1053/j.gastro.2004.09.02115508109
|
3.
|
G FattovichT StroffoliniI ZagniF
DonatoHepatocellular carcinoma in cirrhosis: incidence and risk
factorsGastroenterology127Suppl
1S35S50200410.1053/j.gastro.2004.09.01415508101
|
4.
|
LL WongWM LimmR SeverinoLM WongImproved
survival with screening for hepatocellular carcinomaLiver
Transpl6320325200010.1053/lv.2000.487510827233
|
5.
|
HB El-SeragJR KramerGJ ChenZ DuanPA
RichardsonJA DavilaEffectiveness of AFP and ultrasound tests on
hepatocellular carcinoma mortality in HCV-infected patients in the
USAGut60992997201110.1136/gut.2010.23050821257990
|
6.
|
S BenowitzLiver cancer biomarkers
struggling to succeedJ Natl Cancer
Inst99590591200710.1093/jnci/djk17417440159
|
7.
|
M ShermanCurrent status of α-fetoprotein
testingGastroenterol Hepatol (NY)71131142011
|
8.
|
J BruixM ShermanPractice Guidelines
Committee, American Association for the Study of Liver
DiseasesManagement of hepatocellular
carcinomaHepatology4212081236200510.1002/hep.20933
|
9.
|
Y NakamotoLG GuidottiCV KuhlenP FowlerFV
ChisariImmune pathogenesis of hepatocellular carcinomaJ Exp
Med188341350199810.1084/jem.188.2.3419670046
|
10.
|
NA CacalanoJA JohnstonInterleukin-2
signaling and inherited immunodeficiencyAm J Hum
Genet65287293199910.1086/30251810417270
|
11.
|
R CabreraM AraratM CaoHepatocellular
carcinoma immunopathogenesis: clinical evidence for global T cell
defects and an immunomodulatory role for soluble CD25 (sCD25)Dig
Dis Sci55484495201010.1007/s10620-009-0955-519714465
|
12.
|
B HoechstLA OrmandyM BallmaierA new
population of myeloid-derived suppressor cells in hepatocellular
carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T
cellsGastroenterology135234243200818485901
|
13.
|
B ArunBD CurtiDL LongoElevations in serum
soluble interleukin-2 receptor levels predict relapse in patients
with hairy cell leukemiaCancer J Sci Am62124200010696734
|
14.
|
T ManshouriKA DoX WangCirculating CD20 is
detectable in the plasma of patients with chronic lymphocytic
leukemia and is of prognostic
significanceBlood10125072513200310.1182/blood-2002-06-163912446458
|
15.
|
RG KnodellKG IshakWC BlackFormulation and
application of a numerical scoring system for assessing
histological activity in asymptomatic chronic active
hepatitisHepatology1431435198110.1002/hep.1840010511
|
16.
|
JM LlovetC BrúJ BruixPrognosis of
hepatocellular carcinoma: the BCLC staging classificationSemin
Liver Dis19329338199910.1055/s-2007-100712210518312
|
17.
|
F TrevisaniPE D’IntinoAM
Morselli-LabateSerum alpha-fetoprotein for diagnosis of
hepatocellular carcinoma in patients with chronic liver disease:
influence of HBsAg and anti-HCV statusJ
Hepatol34570575200110.1016/S0168-8278(00)00053-211394657
|
18.
|
T SassaT KumadaS NakanoT UematsuClinical
utility of simultaneous measurement of serum high-sensitivity
des-gamma-carboxy prothrombin and Lens culinaris agglutinin
A-reactive alpha-fetoprotein in patients with small hepatocellular
carcinomaEur J Gastroenterol
Hepatol1113871392199910.1097/00042737-199912000-00008
|
19.
|
Y ShimauchiM TanakaR KuromatsuA
simultaneous monitoring of Lens culinaris agglutinin A-reactive
alpha- fetoprotein and des-gamma-carboxy prothrombin as an early
diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic
patientsOncol Rep72492562000
|
20.
|
JA MarreroGL SuW WeiDes-gamma
carboxyprothrombin can differentiate hepatocellular carcinoma from
nonmalignant chronic liver disease in American
patientsHepatology3711141121200310.1053/jhep.2003.50195
|
21.
|
JA MarreroZ FengY WangAlpha-fetoprotein,
des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in
early hepatocellular
carcinomaGastroenterology137110118200910.1053/j.gastro.2009.04.00519362088
|
22.
|
BI CarrF KankeM WiseS SatomuraClinical
evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein
and des-gamma-carboxy prothrombin in histologically proven
hepatocellular carcinoma in the United StatesDig Dis
Sci52776782200710.1007/s10620-006-9541-2
|
23.
|
AS LokRK SterlingJE EverhartHALT-C Trial
GroupDes-gamma-carboxy prothrombin and alpha-fetoprotein as
biomarkers for the early detection of hepatocellular
carcinomaGastroenterology138493502201010.1053/j.gastro.2009.10.03119852963
|
24.
|
S NakamuraK NousoK SakaguchiSensitivity
and specificity of des-gamma-carboxy prothrombin for diagnosis of
patients with hepatocellular carcinomas varies according to tumor
sizeAm J
Gastroenterol10120382043200610.1111/j.1572-0241.2006.00681.x16848811
|
25.
|
RK SterlingEC WrightTR MorganFrequency of
elevated hepatocellular carcinoma (HCC) biomarkers in patients with
advanced hepatitis CAm J
Gastroenterol1076474201210.1038/ajg.2011.31221931376
|
26.
|
AM Di BisceglieRK SterlingRT ChungHALT-C
Trial GroupSerum alpha-fetoprotein levels in patients with advanced
hepatitis C: results from the HALT-C trialJ
Hepatol43434441200516136646
|
27.
|
SK YoonNK LimS HaThe human cervical cancer
oncogene protein is a biomarker for human hepatocellular
carcinomaCancer
Res6454345441200410.1158/0008-5472.CAN-03-366515289352
|
28.
|
ME el-HouseiniMS MohammedWM ElshemeyTD
HusseinOS DesoukyAA ElsayedEnhanced detection of hepatocellular
carcinomaCancer Control12248253200516258497
|
29.
|
MF YuenCL LaiScreening for hepatocellular
carcinoma: survival benefit and cost-effectivenessAnn
Oncol1414631467200310.1093/annonc/mdg40014504044
|
30.
|
JA DavilaL HendersonJR KramerUtilization
of surveillance for hepatocellular carcinoma among hepatitis C
virus-infected veterans in the United StatesAnn Intern
Med1548593201110.7326/0003-4819-154-2-201101180-0000621242365
|
31.
|
B DanieleA BencivengaAS MegnaV
TinessaAlpha- fetoprotein and ultrasonography screening for
hepatocellular carcinomaGastroenterology127Suppl
1S108S112200410.1053/j.gastro.2004.09.02315508073
|
32.
|
MS PepeR EtzioniZ FengPhases of biomarker
development for early detection of cancerJ Natl Cancer
Inst9310541061200110.1093/jnci/93.14.105411459866
|